Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 14/20 | 0.42 |
| ▸ | CYBB | P04839 | 5/20 | 0.41 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211140 | 0.80 | HTR1A (0.45) | NCF1CYBBNOX5HTR1BNPC1 | |
| SCHEMBL5218606 | 0.74 | GRM5 (0.44) | NPC1ALDH1A1MAPTRAB9APOLB | |
| SCHEMBL5206891 | 0.73 | HTR1D (0.56) | NCF1CYBBNOX5HTR1B | |
| SCHEMBL9184287 | 0.72 | NCF1 (0.46) | NCF1CYBBNOX5HTR1BNPC1 | |
| SCHEMBL9186984 | 0.71 | NCF1 (0.49) | NCF1CYBBNOX5HTR1BKCNA3 | |
| SCHEMBL2164367 | 0.70 | NCF1 (0.51) | NCF1CYBBNOX5HTR1BKCNA3 | |
| SCHEMBL5209710 | 0.70 | NCF1 (0.48) | NCF1CYBBNOX5 | |
| SCHEMBL5211096 | 0.70 | NCF1 (0.48) | NCF1CYBBNOX5 | |
| SCHEMBL23412378 | 0.68 | MAPT (0.52) | NCF1CYBBNOX5HTR1BNPC1 | |
| SCHEMBL2204553 | 0.68 | HTR1B (0.67) | HTR1BKCNA3NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | NCF1 839/4885CYBB 688/4885NOX5 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.